TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A female who enrolled in the immunological subset of the 580299-013 study, received the three doses of vaccine/control according to the treatment allocation and completed the 580299-013 study.~* Written informed assent obtained from the subject and written informed consent obtained from a parent or legally acceptable representative of the subject.~Exclusion Criteria:~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).~* Use of any investigational or non-registered product (drug or vaccine) or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs occurring less than 3 months prior to blood sampling.~* Administration of immunoglobulins and/or any blood products within the 3 months preceding blood sampling.

- Gender: FEMALE
- Minimum Age: 10 Years
- Maximum Age: 14 Years
- Healthy Volunteers: t

Study Arms:
- Cervarix Group (Type: EXPERIMENTAL): Subjects received 3 doses of GSK Biologicals' HPV-16/18 Vaccine (Cervarix™) during the primary study (NCT00196924). Subjects from this group continued the long-term follow-up study until Month 48.
- Havrix Group (Type: ACTIVE_COMPARATOR): Subjects received 3 doses of Havrix™ (hepatitis A vaccine \[HAV\]) during the primary study (NCT00196924). Subjects from the this group completed the study at Month 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Assessing Cooled Radiofrequency Denervation as a Treatment for Sacroiliac Joint Pain Using the Sinergy System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Predominantly axial pain below L5 vertebrae~* greater than 75%pain relief from 2 seperate lateral branch blocks done on different days~* chronic axial pain lasting longer than 6 months, 3 day average VAS between 4 and 8~* age greater than 18~* failed to acheive adequate improvemnet with comprehensive non-operative treatments, includingbut not limited to: activity alteration, non0steriodal anti-iflammatory, physical and/or manual therap, and flurpscopically guided steriod injections in and around the area of pathology~* all other possible sources oflow back pain have been ruled out, including but not limited to the intervertebral discs, bone fracture.~Exclusion Criteria:~* Beck Depression greater than 20%~* irreversible psychological barriers to recovery~* spinal pathology that may impede recovery such as spins bifida occulta,~* moderate to severe foraminal or central canal stenosis~* systemic infection or localized infection at inducer site~* concomitant cervical or thoracic pain greater than 2/10 on VAS~* uncontrolled or acute disease~* chronic severe condition such as rheumatoid arthritis~* preganancy~* active radicular pain~* immunosuppression~* workers compensation~* allergy to injectants or medications used in procedure~* high narcotis use greater than 30 mg hydrocodone or equivalent~* smokers~* body mass index greater than 29.9

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Treatment with Sinergy system
- 2 (Type: PLACEBO_COMPARATOR): placebo controlled

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: 10-21 years.~2. Sex: male and female subjects will be enrolled.~3. Tanner stage: I-V.~4. T1D duration of \<3 months (i.e., from first insulin injection) to ensure the inclusion of patients in PCR.~5. Presence of at least one diabetes-associated autoantibody.~6. Normal-weight, overweight-, and obese subjects with T1D~7. Fasting serum C-peptide level of \>0.1 nmol/L (0.3 ng/mL)1; or 2-hour post-meal stimulated C-peptide level of 0.2 nmol/L (≥0.6 ng/mL).~Exclusion Criteria:~1. Subjects on weight altering medications, such as orlistat.~2. Subjects with eating disorders~3. Subjects on medications other than insulin that can affect blood glucose level.~4. Subjects with 25-hydroxyvitamin D \[25(OH)D\] levels of \>70 ng/mL, as this may lead to vitamin D toxicity in the study subjects.~5. Subjects with systemic diseases other than T1D.~6. Subjects with recurrent diabetic ketoacidosis (\>2 episodes since the diagnosis of T1D or in the preceding 3 months); or \>2 episodes of severe hypoglycemia in the preceding 3 mo.~7. Pregnant or breast-feeding female subjects.~8. The receipt of any investigational drug within 6 months prior to this trial.~9. Active malignant neoplasm.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Ergocalciferol (Type: EXPERIMENTAL): Oral administration of 50,000 IU of ergocalciferol one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
- Placebo (Type: PLACEBO_COMPARATOR): Oral administration of placebo one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pantoprazole on Insulin Secretion in Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Drug-Naive~* No complications~* HbA1c 7 to \< 9%~* Fasting plasma glucose \< 210mg/dl~* Body mass index 30.0 to 39.9 and body weight stable for at least 3 months before the study~* Non smokers~* Blood pressure \< 130/80~Exclusion Criteria:~* Diabetes complications~* Women pregnant or stage of lactation~* Hepatic, renal, autoimmune disease~* Take drugs with effects on insulin secretion~* Zollinger-Ellison disease~* Gastric or pancreatic tumor.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo of calcined magnesia, capsules
- Pantoprazole (Type: EXPERIMENTAL): The pantoprazole will be administered in 40mg capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Homozygous for the F508del mutation (F/F)~* Forced expiratory volume in 1 second (FEV1) value ≥40% and ≤90% of predicted mean for age, sex, and height~Key Exclusion Criteria:~* Clinically significant cirrhosis with or without portal hypertension~* Lung infection with organisms associated with a more rapid decline in pulmonary status~* Solid organ or hematological transplantation~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TEZ/IVA (Type: ACTIVE_COMPARATOR): Following TEZ/IVA run-in period of 4 weeks, participants received TEZ 100 milligrams (mg) once daily (qd)/IVA 150 mg every 12 hours (q12h) in the treatment period for 24 weeks.
- ELX/TEZ/IVA (Type: EXPERIMENTAL): Following TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients (SETH2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* men aged \> 35 years~* body mass index \> 30 kg/m2~* confirmed hypogonadism~* type 2 diabetes mellitus treated with non-insulin therapy~Exclusion Criteria:~* previously treated hypogonadism~* the 2 diabetes mellitus treated with insulin therapy~* a history of current prostate or breast cancer~* severe benign prostatic hyperplasia~* elevated prostate-specific antigen (PSA \> 4.0 lg/l)~* severe heart failure~* acute coronary event or procedure during the six months leading up to the study~* chronic obstructive lung disease~* hypothyroidism~* severe obstructive sleep apnea (OSA)~* active infection~* rheumatoid arthritis

- Gender: MALE
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Testosterone (Type: ACTIVE_COMPARATOR): Testosterone arm patients were receiving testosterone undecanoate 1000 mg intramuscular injections two years; according to the protocol every 10 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo arm patients were receiving placebo throughout the first year of this study and testosterone undecanoate 1000 mg intramuscular injections during second year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Findings to Adjust the Duration of Anticoagulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* acute proximal DVT associated or not with clinically symptomatic pulmonary embolism~Exclusion Criteria:~* history of previous VTE~* active cancer~* indications for permanent anticoagulation~* contraindications to anticoagulation~* pregnancy~* geographical inaccessibility for long-term follow-up~* life expectancy shorter than 1 year~* refusal of informed consensus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Tailoring the duration of anticoagulation according to the ultrasound persistence of residual vein thrombosis
- 2 (Type: ACTIVE_COMPARATOR): Administering a fixed duration of anticoagulation (i.e., discontinue it at the time of randomization in patients with secondary DVT, and prolong it for 3 additional months in patients with idiopathic DVT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent~* HCV RNA \> 10\^4 IU/mL at screening~* Chronic HCV infection (≥ 6 months)~* Confirmed CPT class B (7-9) at screening~Exclusion Criteria:~* Current or prior history of solid organ transplantation, significant pulmonary disease, significant cardiac disease, or porphyria~* Inability to exclude hepatocellular carcinoma (HCC) by imaging within 6 months of baseline/Day 1~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Screening ECG with clinically significant abnormalities~* Prior exposure to SOF or any other nucleotide analogue HCV nonstructural protein 5B (NS5B) inhibitor or any HCV NS5A inhibitor~* Laboratory results outside of acceptable ranges at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL 12 weeks (Type: EXPERIMENTAL): Participants will receive SOF/VEL FDC for 12 weeks.
- SOF/VEL+RBV 12 weeks (Type: EXPERIMENTAL): Participants will receive SOF/VEL FDC plus RBV for 12 weeks.
- SOF/VEL 24 weeks (Type: EXPERIMENTAL): Participants will receive SOF/VEL FDC for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of an Oral Vaccine to Prevent Avian Influenza

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* In good health as established by medical history, physical examination and laboratory testing at the time of enrollment.~Exclusion Criteria:~* Has had any other vaccines within the past 8 weeks.~* Has had prior H5 avian influenza investigational vaccine.~* Current history of chronic alcohol consumption and/or illicit and/or recreational drug use.~* History of autoimmune related disease.~* History of any confirmed or suspected immunodeficient or immunosuppressive condition (no congenital or acquired condition that impedes normal immune response, no concurrent immunosuppressive therapy).~* Positive serology for HIV, HCV, or HBV.~* Previous serious reactions to vaccination such as anaphylaxis, respiratory problems, hives or abdominal pain.~* History of irritable bowel disease or other inflammatory digestive or gastrointestinal conditions that could affect the intended distribution or safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine.~* Use of proton pump inhibitors (Nexium, Prilosec) that substantially increases stomach pH.~* Stool sample with occult blood at baseline exam

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Experimental Low Dose (Type: EXPERIMENTAL): Biological: One dose of a live replication incompetent adenovirus given in a capsule
- Experimental Medium Dose (Type: EXPERIMENTAL): Biological: One or two doses of replication incompetent adenovirus given in a capsule~Other: Placebo capsules of the same size and shape
- Experimental High Dose (Type: EXPERIMENTAL): Biological: One dose of replication incompetent adenovirus in a capsule
- Placebo Control (Type: PLACEBO_COMPARATOR): Capsules of the same size and shape as the experimental

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females between ages of 18 and 50~* Enrolled in RNP methadone program and stable on methadone for at least 3 weeks~* Current cocaine abuse or dependence according to DSM-IV criteria~* No current medical problems and normal ECG~* If female, not currently pregnant or breast feeding and using reliable birth control~* Fluent in English and have at least a 6th grade reading level~* Can commit to 12 weeks of treatment and are willing to be randomized~Exclusion Criteria:~* Current major psychiatric illness including mood, psychotic or anxiety disorder~* History of major medical illnesses including asthma, chronic obstructive lung disease, gastrointestinal ulcer, hepatic or renal impairment, cardiac rhythm disturbances~* Use of medications including beta blockers and NASAIDs~* Known allergy to Galantamine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Standard Treatment As Usual (TAU) (Type: NO_INTERVENTION): Standard Treatment plus placebo for cocaine abusing or dependent methadone-maintained individuals. This consists of daily methadone visits plus one individual and one group session per week, and patients may participate in additional treatments such as HIV education and treatment. The counseling program's theoretical orientation is described as client-centered.
- TAU Plus Galantamine (Type: EXPERIMENTAL): Standard treatment plus Galantamine. In this study, we will use 8 mg galantamine extended release (ER). Galantamine ER is used once daily. The recommended initial dose is 8 mg/day and the maintenance dose is 16-24 mg/day.
- TAU plus Computer Assisted Cognitive Behavioral Therapy (CBT) (Type: EXPERIMENTAL): TAU plus computer assisted CBT plus placebo. All participants assigned to this condition will also be offered up to 60 minutes per week to work with the CBT for CBT program, onsite at the clinic, in a private space and using a computer provided by the research project. Patients will have the choice of how they choose to use the computer, that is, in two 30-minute sessions or one one-hour session.
- TAU plus CBT plus galantamine (Type: EXPERIMENTAL): Standard treatment, plus computer assisted cognitive behavioral therapy, plus galantamine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Esophageal Hypersensitivity Study in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written consent~* Clinically normal physical findings~* Sensitization potential~Exclusion Criteria:~* Clinically significant illness within 2 weeks prior to the first dose of investigational product~* History of clinically significant disease~* Use of prescribed medication during the 2 weeks before administration of the first dose of investigational product

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 30 mg, oral, single dose
- 2 (Type: EXPERIMENTAL): 95 mg, oral, single dose
- 3 (Type: PLACEBO_COMPARATOR): Oral solution, single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Esmolol Infusion in Patients Undergoing Craniotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with ASA physical status 1-3~* Glasgow Coma Scale:15~Exclusion Criteria:~* Patients with ASA physical status \>3,~* Body Mass Index (BMI) over 30,~* indication for rapid sequence induction,~* any contraindication for receiving b-blocker,~* chronic use of b-blocker,~* Glasgow Coma Scale (GCS) \<15,~* history of drug abuse,~* severe mental impairment,~* preoperative aphasia,~* neurologic deficit or preoperatively foreseen delayed extubation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Esmolol (Type: ACTIVE_COMPARATOR): 500 mcg/kg of esmolol bolus 10 min before induction of anesthesia, followed by additional 200 mcg/kg/min of esmolol until 30 minutes after extubation.
- control (Type: PLACEBO_COMPARATOR): Control group did not receive esmolol or other b-blocker in the perioperative period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Dose Determination Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age of 13 to 30 years~2. Subjects must be otherwise healthy except for T1DM, and treated for hypothyroidism if present~3. Menstruating women must have negative pregnancy test.~4. Hemoglobin (Hb) more than 12 g/dl~Exclusion Criteria:~1. Having any other chronic condition except hypothyroidism stable on medications~2. On chronic medications that may affect glucose excursions~3. Hemoglobin less than 12 g/dl~4. Positive pregnancy test (based on Urine)~5. Pregnant or lactating mothers~6. Known allergy to Januvia

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Part A (Type: ACTIVE_COMPARATOR): Sitagliptin 25mg
- Part B (Type: ACTIVE_COMPARATOR): Sitagliptin 50mg
- Part C (Type: ACTIVE_COMPARATOR): Sitagliptin 100mg
- Part D (Type: PLACEBO_COMPARATOR): Placebo oral tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete